GOLDENWELL BIOTECH, INC. — Net Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5245bfc5-d87e-48e7-a542-dea0f5accc85/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-296.5k | 2025-01-01 – 2025-12-31 | evidence 0001477932-26-004130 |
| FY 2024 | $-131.5k | 2024-01-01 – 2024-12-31 | evidence 0001477932-25-003784 |
| FY 2023 | $-117.4k | 2023-01-01 – 2023-12-31 | evidence 0001477932-25-003784 |
| FY 2022 | $-985.1k | 2022-01-01 – 2022-12-31 | evidence 0001477932-23-002478 |
| FY 2021 | $-117.0k | 2021-01-01 – 2021-12-31 | evidence 0001477932-22-001951 |
| FY 2020 | $-6.3k | 2020-01-01 – 2020-12-31 | evidence 0001477932-21-004870 |
| FY 2019 | $-2.3k | 2019-01-01 – 2019-12-31 | evidence 0001477932-21-004870 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
GOLDENWELL BIOTECH, INC. — all facts · Revenue · Operating Income